News & Events RSS Feed

16 October 2017

Final Results for the year ended 30 June 2017

  Chairman's Statement Summary of Results in the year ended 30 June 2017 Total income (revenue and grant income) decreased 9% to £270,465 (2016: £297,120) The operating loss before exceptional costs increased 20% to £489,190 (2016: £408,614) The loss for the year attributable to equity shareholders increased 6% to £400,526 (2016: £378,697) On 30 June […]

2 October 2017

Company Update

Physiomics plc (AIM: PYC) is pleased to announce positive developments relating to its core oncology and simulation business and to provide commentary on potential business collaborations and progress in diversifying into the personalised medicine space. For more information please click here.  

31 July 2017

Two new pre-clinical contracts

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating to a new oncology target.  Please see here for further information

6 June 2017

Physiomics to attend PAGE 2017

Oxford, UK, 6th June 2017: Physiomics is pleased to announce that it will attend the Population Approach Group Europe (PAGE) Annual Conference taking place in Budapest, Hungary 7-9 June. PAGE is Europe’s premier conference focused on Quantitative Pharmacology and attracts the top biotech, pharma executives as well as academics working in the field. Physiomics will […]

24 May 2017

Update: two further extension projects to advance oncology candidate with global pharma company

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been contracted for two further extensions to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012. Please see here for more information.

5 May 2017

Physiomics to Present at BioTrinity 2017

Oxford, UK, 5th May 2017: Physiomics is pleased to announce that it will attend BioTrinity 2017. BioTrinity is one of Europe’s leading Biopartnering and Investment Conferences, to be held on 8-10 May at the Novotel London West. In addition to participating in a number of partnering meetings, Physiomics will present an update on its technology […]

24 March 2017

Interim Results Statement for the six month period ended 31 December 2016

Oxford, UK, 24 March 2017: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2016. Physiomics Plc is a computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings […]

Page 1 of 2212345...1020...Last